top of page
Whre We Hep
IF IT’S A QUESTION OF ACCESS, WE'LL HELP YOU FIND THE ANSWERS
Pharma companies use ValueBase to answer the big questions. Our solutions track the access environment over time, unlocking rich datasets that inform decision-making at every stage of the product lifecycle.
In-market multidisciplinary teams rely on our data insights to support:
• Commercial/brand strategy
• Business development
• Forecasting
• Product launch
• Strategy adjustment/refinement
• Loss of Exclusivity (LoE) planning
Click the buttons below to see some of the questions we can help you answer in 3 core areas:
Our Solutions
THE COMPLETE PICTURE. ALL DAY, EVERY DAY
Our digital access tools provide the complete picture of availability, access and adoption of medicines in five key European markets.
We monitor the market 24/7, allowing businesses to detect and respond to change as it happens or review trends over time.
Our solutions empower brand teams with real-world intelligence that drives competitive advantage – and helps unlock equitable access to medicines.
Formulytics tracks medicines formularies all day, every day – detecting updates the day they happen.
It allows businesses to monitor product availability and adoption, benchmark competitors, identify early adopters and respond to gaps in access. Formulytics makes the invisible visible. Quickly and accurately.
In some countries, guidelines sit separately to formularies.
Guidelight can provide a real-time view of local guidelines. Once a therapy area is coded, it monitors the environment 24/7, capturing updates for every published guideline and every locality.
Our FOI system monitors updates to unpublished guidelines too, giving customers a 360° view of positioning, prescribing options and recommendations.
Our proprietary indexing tool, the Availability Index is a standard measure of access for every product that allows companies to compare the access availability of products within a locality and across regions.
It takes account of the initiating prescriber, the positioning and restrictions noted within the relevant access documents.
bottom of page